Recordati and Moderna Team Up to Advance mRNA Therapy for Propionic Acidemia
Recordati has entered a strategic collaboration with Moderna to develop and commercialize mRNA-3927 for propionic acidemia (PA). The deal includes a $50 million upfront payment, up to $110 million in near-term milestone payments, and tiered royalties, while pivotal data are expected by the end of 2026. Recordati says material EBITDA effects are not…